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ABSTRACT
Background: We previously reported that ‘benifuuki’ green tea containing O-methylated catechin significantly
relieved the symptoms of perennial or seasonal rhinitis compared with a placebo green tea that did not contain
O-methylated catechin in randomized double-blind clinical trials. In this study we assessed the effects of ‘beni-
fuuki’ green tea on clinical symptoms of seasonal allergic rhinitis.
Methods: An open-label, single-dose, randomized, parallel-group study was performed on 38 subjects with
Japanese cedar pollinosis. The subjects were randomly assigned to long-term (December 27, 2006 ― April 8,
2007, 1.5 months before pollen exposure) or short-term (February 15, 2007: after cedar pollen dispersal ― April
8, 2007) drinking of a ‘benifuuki’ tea drink containing 34 mg O-methylated catechin per day. Each subject re-
corded their daily symptom scores in a diary. The primary efficacy variable was the mean weekly nasal symp-
tom medication score during the study period.
Results: The nasal symptom medication score in the long-term intake group was significantly lower than that
of the short-term intake group at the peak of pollen dispersal. The symptom scores for throat pain, nose-
blowing, tears, and hindrance to activities of daily living were significantly better in the long-term group than the
short-term group. In particular, the differences in the symptom scores for throat pain and nose-blowing between
the 2 groups were marked.
Conclusions: We conclude that drinking ‘benifuuki’ tea for 1.5 months prior to the cedar pollen season is ef-
fective in reducing symptom scores for Japanese cedar pollinosis.
KEY WORDS
‘benifuuki’ green tea, epigallocatechin-3-O- (3-O-methyl)-gallate (EGCG3”Me), Japanese cedar pollinosis,
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INTRODUCTION
Seasonal allergic rhinitis (SAR) is a very common dis-
ease in developed countries, and its occurrence has
been increasing in recent years. The prevalence of
Japanese cedar pollinosis, the most common SAR in
Japan, is estimated to be approximately 16.2% of the
population.1 Since medical costs for treating the dis-
ease are large and possible adverse effects of avail-
able medication are not negligible, there is a greater
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Fig. 1 The chemical structure of epigalocatechin-3-O-(3-
O-methyl) galate (an O-methylated catechin).
demand for the development of physiologically-
functional foods for allergy prevention.
Tea (Camellia sinensis L.) is consumed globally
and in large quantities in Japan and China, where it
has been used not only as a daily beverage but also
for medicinal purposes for thousands of years. Tea
has been found to exhibit various bioregulatory activi-
ties,2,3 such as anti-carcinogenic, anti-metastatic, anti-
oxidative, anti-hypertensive, anti-hypercholesterolemic,
anti-dental caries, and anti-bacterial activities and to
contribute to intestinal flora amelioration. Catechins,
a group of polyphenolic compounds, have been shown
to be largely responsible for these effects. Catechins
play a significant role in anti-allergic responses.
We have reported that O-methylated EGCGs (epi-
gallocatechin-3-O-[3-O-methyl] gallate [EGCG3”Me;
Fig. 1], epigallocatechin-3-O-[4-O-methyl] gallate
[EGCG4”Me]),4-7 and strictinin8 have anti-allergic
functions and that the Japanese tea cultivar ‘beni-
fuuki’ is rich in EGCG3”Me, which is not present in
black tea.9,10 Oral administration of these methylated
catechins, significantly and dose-dependently (5―50
mgkg), inhibited type I allergic (anaphylactic) reac-
tions in mice sensitized with ovalbumin and Freund’s
incomplete adjuvant.4 These catechins also strongly
inhibit mast cell activation through the prevention of
tyrosine phosphorylation (Lyn, Syk, and Btk) of cellu-
lar proteins, histamine and leukotriene release, and
interleukin-2 secretion after Fc Epsilon RI cross-
linking.7 Furthermore, we reported the in vitro and in
vivo effects of ‘benifuuki’ green tea containing O-
methylated catechin and a combination of food com-
ponents that work synergistically with ‘benifuuki’
such as in inflammatory cytokine production from
mast cells after antigen stimulation, symptom relief,
and safety of subjects with Japanese cedar pollinosis
(in a double-blinded clinical trial). We also reported
on the blood levels of unconjugated EGCG and
EGCG3”Me after giving ‘benifuuki’ green tea to hu-
mans.11 In a previous paper, a double-blinded clinical
study on subjects with Japanese cedar pollinosis was
carried out to evaluate the effects and safety of ‘beni-
fuuki’ green tea, containing EGCG3”Me, and a combi-
nation of ‘benifuuki’ green tea and ginger extract,
compared with ‘yabukita’ green tea as a placebo. The
‘benifuuki’ and ‘yabukita’ green tea contained 44.7 mg
and 0 mg of EGCG3”Me, 176.1 mg and 202.8 mg of
EGCG, 71.4 mg and 84.6 mg of caffeine, and 432 mg
and 425 mg of total catechin per 3 g, respectively. As
the cedar pollen increased, the symptoms of pollino-
sis became exacerbated in the placebo group com-
pared with the ‘benifuuki’ group. During the most se-
vere cedar pollen period, 11 weeks after starting the
treatment, the symptoms such as nose-blowing and
itchy eyes, showed significant improvement in the
‘benifuuki’ group compared with the control group (P
< 0.05). Among the groups, there were no clinically-
relevant changes in the hematological examination,
general biochemical examination, total IgG antibody
titer, serum iron content, or interview results
throughout the intake period. We also concluded that
drinking ‘benifuuki’ green tea for over 1.5 months
was useful in improving some Japanese cedar pollino-
sis symptoms while causing no effects in normal im-
mune responses in subjects with seasonal rhinitis.
However, it was not clear regarding when to initiate
the drinking in order to optimize the beneficial effects
of the tea. Therefore, in this study, we examined the
efficacy of ‘benifuuki’ green tea in Japanese cedar pol-
linosis during the most prevalent season for allergic
rhinitis in Japan, focusing on the effects of the drink-
ing period on symptom improvement. We found that
early initiation of drinking before the pollen season is
significantly more effective than later initiation at the
time of pollen exposure.
METHODS
PREPARATION OF THE ‘BENIFUUKI’ GREEN
TEA DRINK
‘Benifuuki’ tea was extracted at 90℃ for 6 minutes in
a 30-fold dilution with distilled water (WV). During
the extraction, each infusion was stirred for 10 sec-
onds every minute. After filtration, L-ascorbic acid
and sodium bicarbonate were added to the tea infu-
sions, and the concentration of polyphenol (tannin12)
in the infusion was standardized. Thereafter, the tea
infusion was pasteurized at 138℃ for 30 seconds and
poured into 350-ml plastic bottles (PET). The cate-
chin and caffeine contents of the test drink were
measured by high performance liquid chromatogra-
phy (HPLC), as shown in Table 1.
SUBJECTS
We recruited 38 individuals with Japanese cedar polli-
nosis, aged between 25―60 years. All subjects had a
history of seasonal rhinitis for at least the last 2 Japa-
nese cedar pollen seasons and a positive Japanese ce-
dar pollen-specific IgE value. We excluded subjects
who had specific immunotherapy against Japanese
cedar pollen disease in the past 2 years, or active or
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Table 1 The catechin and cafeine contents of the test 
drink
mg/100 mLComponent
 6.72O-methylated EGCG
15.64EGCG
25.59GCG
 4.64ECG
 9.56EGC
 4.05EC
21.84Cafeine
Week 0    1     2    3   4    5   6    7   8    9    10   11  12   13  14   15
Visit 1
Dec/18/06 
No treatment; 
Baseline
screening phase 
Randomization 
Start to drink (L) 
Dec/27/06 
Start to drink (S)
Feb/15/07 
Symptom diary 
Short-term intake group (‘benifuuki’ green tea drink; 34 mg/day) 
Long-term intake group (‘benifuuki’ green tea drink; 34 mg/day) 
Drinking stops, 
collection of diary 
Apr/08/07 
Fig. 2 Study schedule.
Table 2 The characteristics of the participants enroled in 
this study
Short-term drinkingLong-term drinking
1919N
40.9±10.541.0±9.8Age (mean)
Gender
1213Male
 6 5Female
Nasal SS
3.0±1.13.2±0.7(starting point)
recent developments (within 3 months) of any other
type of rhinitis, pregnant or nursing women, and pa-
tients with serious medical conditions. Table 2 shows
the characteristics of the subjects in terms of age,
gender, and the severity of nasal symptoms at the
starting point.
STUDY DESIGN
An open-label, single-dose, randomized, parallel-
group study was performed at National Institute of
Vegetable and Tea Sciences (NIVTS) in Shizuoka and
Mie, Japan, between December 2006 and April 2007.
The study protocol was approved by the Institutional
Review Board of the NIVTS for Human Research and
was carried out in accordance with the Declaration of
Helsinki. Written informed consent was obtained
from all participants before participation.
During the study period, all subjects consumed 2
bottles of ‘benifuuki’ green tea (350-ml PET drink)
each day. As shown in Figure 2, the test began on De-
cember 18, 2006, approximately 7 weeks before the
cedar pollen season. The 38 subjects were randomly
assigned to the long-term intake group or the short-
term intake group. Tea intake began on December
27, 2006 for the long-term intake group and contin-
ued until April 8, 2007, and the short-term intake
group began their intake from February 15, 2007 to
April 8, 2007. All tests were completed on April 8,
2007.
SYMPTOM ASSESSMENT
During the test period, all subjects were required to
record allergic symptoms in a diary, including the
daily frequency of sneezing and nose-blowing, stuffy
nose, itchy eyes, tears, throat pain, hindrance to ac-
tivities of daily living (ADL), and the use of medica-
tion, in accordance with the method proposed by the
Japanese Society of Allergology Allergic Rhinitis
Committee. Symptoms were evaluated using a 5-point
scale: 0, no symptoms; 1, mild; 2, moderate; 3, severe;
4, very severe symptoms present all day. The diaries
were collected at the end of the study, and were used
to first evaluate the Nasal Symptom Score (NSS) and
Eye Symptom Score (ESS). The Nasal Medication
Score was then calculated as the sum of the daily na-
sal rescue medication scores: use of a second-
generation antihistamine or a histamine-release sup-
pressor was scored as 1 point, use of a local corti-
Maeda-Yamamoto M et al.
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Fig. 3 The mean 1-week Nasal SMS of changes found in 
subjects given ‘benifuuki’ green tea in the long-term and 
short-term intake groups. Circles represent the long-term in-
take group; solid dots represent the short-term intake group. 
Solid triangles represent the scatering number of Japanese 
cedar polen. The mean 1-week Nasal Symptom Medication 
Score of changes found in subjects given ‘benifuuki’ green 
tea. A comparison between the long-term intake group and 
the short-term intake group was performed using the Mann-
Whitney U-test.＊P＜0.05 vs. another group.
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costeroid as 2 points, nasal application of a vasocon-
strictor or an anticholinergic drug as 1 point, and use
of an oral corticosteroid mixed histamine-release sup-
pressor as 3 points, based on the guidelines for aller-
gic rhinitis management of the Japan Allergy Founda-
tion.13 The rescue medications used by the subjects
were RizabenⓇ, AllelockⓇ, AllegraⓇ, EbastelⓇ, Stac
nyscapⓇ, Rohto rhinitis soft capsuleⓇ, AlguardⓇ, His-
poranⓇ, and CelestamineⓇ. Finally, the Nasal Symp-
tom Medication Score (Nasal SMS) was calculated as
the sum of the daily NSS and the daily nasal medica-
tion score. The primary efficacy variable was the aver-
age weekly Nasal SMS during the examination pe-
riod. Secondary efficacy variables included weekly
symptoms.
POLLEN COUNTS
The Japanese cedar pollen counts in the Shizuoka
and Mie area that were announced during the study
by Kissei Pharmaceutical Co., Ltd (Nagano, Japan)
were used. Data were expressed as the means per
week.
The Japanese cedar pollen dispersion period
started at the beginning of February and ended at the
end of April. The long-term intake group began the
first consumption of tea at least 1 month prior to the
estimated starting date of the Japanese cedar pollen
dispersion period, and the drinking period for the
short-term intake group began at the start of the pe-
riod.
CALCULATION OF AREA UNDER THE CURVE
(AUC) VALUES
To evaluate the differences between symptom scores,
the AUC values at the first peak of the pollen season
(February 4 ― March 25) were calculated. The aver-
age AUC values of each symptom score for each
group were calculated daily to give the sum of the
scores for each subject during the period.
STATISTICAL ANALYSIS
Data were expressed as the mean per week or AUC ±
SD. Differences in individual symptom scores, total
symptom scores for each week, and each AUC value
at the first peak of the pollen season were evaluated
between the 2 groups using the Mann-Whitney U
test, assuming a significance level of 5% or 1% using
Statcel software (ver. 2).
RESULTS
SUBJECT CHARACTERISTICS
Of the 38 subjects, 1 subject in the long-term intake
group and 1 subject in the short-term intake group
dropped out from the study because of personal rea-
sons. The remaining 36 subjects were enrolled in the
study (18 in the long-term group and 18 in the short-
term group). No significant differences were found
between the long-term and short-term intake group
with respect to patient characteristics (Table 2). A
high overall compliance rate (more than 95%) was ob-
tained. There were no significant differences in the
baseline symptom scores for sneezing, nose-blowing,
stuffy nose, itchy eye, tears, or throat pain between
the groups (Fig. 3, 4), but the baseline symptom
scores for hindrance to ADL in the long-term intake
group were significantly higher than those of the
short-term intake group (P < 0.01).
EFFICACY
The effects of long-term ‘benifuuki’ green tea intake,
beginning before pollen dispersion, on allergic symp-
toms were examined by comparing the time-course
changes in 3 nasal or 4 non-nasal symptom scores in
the long-term intake group with those of the short-
term intake group, which began tea intake after pol-
len scattering began. (Fig. 3, 4). All symptom scores
increased as the pollen count increased.
At weeks 8, 9, 10, and 12, the mean Nasal SMS,
which was the primary efficacy variable, of the long-
term intake group was significantly lower than that of
the short-term intake group (P < 0.01 or 0.05) (Fig.
3).
The long-term intake group had a significantly
lower incidence of nose-blowing at weeks 8, 9, 10,
and 12 (Fig. 4b); itchy eyes at week 12 (Fig. 4d);
tears at weeks 8, 10, 11, and 12 (Fig. 4e); throat pain
at weeks 8, 9, 10, 11, and 12 (Fig. 4f); hindrance to
ADL at weeks 8 and 11 (Fig. 4g); and NSS at weeks 8
and 12 (Fig. 4h) compared with the short-term intake
The Efficacy of Benifuuki Tea against Pollinosis
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Fig. 4-1 Mean nasal and eye symptom scores, throat pain, and hindrance to activities of daily living of the changes in 1-week 
symptoms of subjects given ‘benifuuki’ green tea in the long-term and short-term intake groups. Circles represent the long-term 
intake group; solid dots represent the short-term intake group. Solid triangles represent the scatering number of Japanese ce-
dar polen. a: sneezing, b: nose-blowing, c: stufy nose, d: itchy eye, e: tears, f: throat pain. A comparison between the long-
term intake group and the short-term intake group was performed using the Mann-Whitney U test.＊＊P＜0.01, ＊P＜0.05 vs. an-
other group.
group. The differences in throat pain and nose-
blowing symptom scores between the 2 groups were
marked.
As shown in Table 3, the AUC of Nasal SMS, nose-
blowing, tears, throat pain, and hindrance to ADL in
the long-term intake group were significantly lower
than that of the short-term intake group at the first
peak of the pollen season (P < 0.01; Nasal SS, nose-
blowing, tears, throat pain, P < 0.05; hindrance to
ADL). On the contrary, sneezing in the long-term in-
Maeda-Yamamoto M et al.
442 Allergology International Vol 58, No3, 2009 www.jsaweb.jp
0
50
100
150
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Ja
pa
ne
se
 c
ed
ar
 p
ol
le
n 
(g
ra
in
s/
da
y/
cm
3 )
S
ym
pt
om
 s
co
re
h
＊
long-term drinking 
short-term drinking 
(weeks)
0
50
100
150
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Ja
pa
ne
se
 c
ed
ar
 p
ol
le
n 
(g
ra
in
s/
da
y/
cm
3 )
S
ym
pt
om
 s
co
re
i
long-term drinking 
short-term drinking 
(weeks)
0
50
100
150
0.0 
0.5 
1.0 
1.5 
2.0 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Ja
pa
ne
se
 c
ed
ar
 p
ol
le
n 
(g
ra
in
s/
da
y/
cm
3 )
S
ym
pt
om
 s
co
re
g
long-term drinking 
short-term drinking 
(weeks)
＊＊ ＊＊
＊＊
＊＊
＊＊
＊＊
＊＊＊＊＊＊＊＊＊＊＊
＊＊
Fig. 4-2 g: hindrance to activities of daily living, h: nasal symptom score, i: eye symptom score.
Table 3 The area under the curve (AUC) of symptom scores during the first peak of the polen season
P
(Mann-Whitney U test)
Z
(Mann-Whitney U test)
AUC in
short-term intake
AUC in
long-term intake
Symptoms/AUC
(Feb. 4―Mar. 25)
0.0332.12871.1±29.975.2±28.2Sneezing
7.95E-095.76973.7±36.261.3±36.1Nose-blowing
0.3550.92751.3±29.048.5±25.0Stufy nose
0.7320.34157.6±32.556.6±32.6Itchy eyes
1.92E-054.27335.3±32.229.3±39.6Tear
7.79E-116.50442.6±33.527.9±26.9Throat pain
0.01992.32843.5±26.637.7±26.5Hindrance to activitiesof daily living
0.1551.42288.3±28.684.7±23.7Nasal symptom score
0.3200.99460.4±31.962.9±35.6Eye symptom score
5.23E-043.468103.4±37.8 91.7±28.3Nasal symptommedication score
Data are expressed as the mean of the AUC for each subject during the first peak of the polen season (Feb. 4 to Mar. 25)±SD.
A comparison between the long-term intake group and the short-term intake group was performed using the Mann-Whitney U test.
take group was significantly higher than that of the
short-term intake group (P < 0.05).
During the study period, no adverse events were
observed. Some physical disorders such as cold
symptoms (6 subjects), nausea (1 subject), and stom-
achache (2 subjects) were reported. There were no
differences in the number of disorders between the 2
groups. None of the conditions were related to the in-
take of the test drink except the stomachache. The
subjects that complained of stomachache were in-
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structed not to consume the test beverage when fast-
ing, because of its rich polyphenol content.
DISCUSSION
Previous randomized, double-blind, and placebo-
controlled clinical studies of ‘benifuuki’ green tea as a
treatment for seasonal allergic rhinitis11 and peren-
nial allergic rhinitis14,15 have demonstrated that
drinking the tea, corresponding to an intake of 34
mgday of O-methylated catechin, markedly im-
proves the symptoms of allergic rhinitis. However,
the optimal starting period for drinking ‘benifuuki’
green tea was not elucidated. The present random-
ized, open-label, parallel-group study provided clinical
evidence that the drinking tea 1.5 months prior to the
Japanese cedar pollen dispersion period is effective in
improving symptoms against SAR.
We have previously demonstrated that O-
methylated catechin and ‘benifuuki’ green tea have
strong anti-allergic effects in vitro. O-methylated
EGCG strongly inhibits the activation and degranula-
tion of murine bone marrow derived mast cells and
human basophilic KU812 cells through the inhibition
of tyrosine phosphorylation (Lyn, Syk, and Btk) of
cellular proteins,7 myosin light chain phosphoryla-
tion,16 and the expression of FcεRI.6 Therefore, we
speculated that the potent anti-allergic activities of O-
methylated EGCG might explain the clinical effects of
‘benifuuki’ green tea, which contains high amounts of
O-methylated EGCG, on allergic rhinitis.
Our previous clinical study on cedar pollinosis
demonstrated that drinking ‘benifuuki’ green tea con-
taining 34 mgday of O-methylated catechin over 1.5
months before pollen dispersion significantly relieved
nose-blowing and itchy eyes compared with drinking
a placebo green tea containing no O-methylated cate-
chin during the most severe cedar pollen dispersion
period.11 Another of our previous studies on mild per-
ennial allergic rhinitis showed that the scores for na-
sal and eye symptoms of the ‘benifuuki’ green tea (34
mgday of O-methylated catechin) intake group were
significantly lower than that of a group that drank
‘yabukita’ at weeks 7―12 for nasal symptom scores,
and at weeks 4―12 for eye symptom scores.15
This study showed that the Nasal SMS, NSS, nose-
blowing, itchy eyes, tears, throat pain, and hindrance
to ADL scores after 1.5 months of consecutive intake
of ‘benifuuki’ green tea before pollen dispersion
(long-term intake group) were significantly lower
than that of the short-term intake subjects who began
their intake after pollen scattering during the most
severe cedar pollen scattering period. Furthermore,
the AUCs of the Nasal SMS, nose-blowing, tears,
throat pain, and hindrance to ADL in the long-term in-
take group were significantly lower than those of the
short-term intake group at the first peak of the pollen
season. These results suggest that a 1.5-month con-
secutive intake of ‘benifuuki’ green tea prior to pollen
exposure is necessary to produce the desired effi-
cacy.
The score of hindrance to ADL from weeks 0 to 6
in the long-term intake group was significantly higher
than that of the short-term intake group. We surmise
that this difference is only owing to the difference of
baseline.
Inhibitory effects were clearly identified in short-
term in vitro experiments, but this was not the case
in clinical tests. Several reasons may account for this
discrepancy. First, pollinosis symptoms are not only
caused by mast cells but also by other inflammatory
cells of the immune system. Although mast cells play
a critical role as initiators of IgE-dependent immedi-
ate hypersensitivity17 and the suppression of mast
cell activation eventually leads to suppression of the
entire inflammatory response, this process may take
time. Secondly, the mast cells may have already been
primed before the pollen season because the immu-
nological microenvironment of patients with seasonal
allergic rhinitis shifts to Th2- mediated responses.18
Thus, at allergen exposure the ‘primed’ mast cells
would induce an enhanced allergic inflammatory cas-
cade. Therefore, we concluded that O-methylated
EGCG is more effective at restraining the primed
mast cell activation that occurs prior to antigen expo-
sure and thereby suppresses the symptoms of polli-
nosis during the cedar pollen season. It has been re-
ported that early treatment with antihistamine or anti-
leukotriene drugs before cedar pollen dispersal is
very effective.19 The present clinical effects of long-
term intake of O-methylated catechins are in agree-
ment with these studies. We suspect that the crucial
step for its efficacy may be effective inhibition of
primed mast cells before the appearance of an inflam-
matory cascade.
The main pillar in the management of seasonal al-
lergic rhinitis is drug treatment such as antihista-
mines and topical corticosteroids20; however, it is
more desirable to relieve the symptoms by modifying
lifestyles, for example, by choosing a “better” tea that
is consumed every day. The amount of ‘benifuuki’
taken daily in this study is not an excessive amount.
Therefore, a patient with seasonal allergic rhinitis
may be able to manage hisher symptoms by drink-
ing ‘benifuuki’ green tea regularly. We conclude that
drinking ‘benifuuki’ green tea for 1.5 months prior to
cedar pollen season is effective in reducing the symp-
tom scores for Japanese cedar pollinosis compared
with a short-term intake group which began tea in-
take after pollen scattering began.
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